The IPO's closing is contingent on Nasdaq listing approval and SEC effectiveness — watch for EFFECT notice and final pricing announcement. The offering provides a ~US$12.2M net lifeline to a company with an accumulated deficit of C$27M and an SEC-acknowledged going concern risk. Post-offering liquidity improves substantially but US market entry (psilocybin/MDMA rescheduling) is not expected within 12 months. Monitor next 8-K for pricing and effectiveness.
Executive Summary
Optimi Health Corp., a Canadian GMP-compliant psychedelic pharmaceutical manufacturer, filed Amendment No. 8 (F-1/A) to its US IPO registration statement on May 19, 2026, updating the prospectus with a preliminary offering of 2,500,000 common shares at an expected price range of US$6.00-$8.00 per share, with an over-allotment option of 375,000 shares. This amendment updates the underwriter warrants from 143,750 to 115,000 shares, updates the CSE reference price to C$9.45 per share as of May 15, 2026, and moves the IPO process closer to effectiveness. The filing remains preliminary — the SEC has not yet declared the registration statement effective, and Nasdaq listing is still a condition to closing.
Key Financial Metrics
Key Facts
- Offering of 2,500,000 common shares at expected price of US$6.00-$8.00 per share, with up to 375,000 additional shares available under over-allotment option.
- CSE reference price as of May 15, 2026: C$9.45 per share (post-split equivalent); OTCQX closing price was US$7.14.
- Underwriter warrant shares reduced from 143,750 to 115,000 (4% of total securities sold, including over-allotment).
- LIFE Offering Exemption in Canada used for Canadian sales; primary offering is a US IPO on Form F-1.
- Estimated net proceeds at low end: ~US$12.2M ($14.3M with over-allotment), allocated ~28.7% to scaling production/distribution, ~18% to market entry (Israel, US), ~53.3% to general working capital.
- Reverse share split (1-for-30) approved by Board, to take effect immediately prior to effectiveness of the registration statement — intended to meet Nasdaq minimum bid price requirement.
- Company has applied to list on Nasdaq under symbol OPTH; listing is a condition to closing this offering.
- Company has recurring operating losses: FY2025 net loss of C$3.7M, accumulated deficit of C$27.2M as of Dec 31, 2025.
- Drug products revenue of C$303K in FY2025 (71% of total), vs C$11K in FY2024 — shift from nutraceutical focus.
- Post-offering shareholder dilution: new investors at US$6.00/share face immediate dilution of US$3.23/share ($2.77 pro forma NAV vs $6.00 offering price).
Financial Impact
Up to ~US$15.0M gross proceeds at low-end IPO price of US$6.00/share; net proceeds of ~US$12.2M after underwriting discounts and expenses. Pro forma cash increases from C$0.49M to C$17.2M.
Risk Factors
- Going concern risk — company has never achieved profitability; reliant on this offering for near-term survival.
- Nasdaq listing not yet approved; offering automatically cancelled if application is denied.
- US market entry requires DEA rescheduling of Schedule I substances and FDA approval — timelines uncertain and could take years.
- Reverse share split (1:30) required to meet Nasdaq minimum bid — execution risk and potential for post-split price volatility.
- IP risk: no patents, no pending patent applications; U.S. trademark applications abandoned after cease and desist letter.
- Concentration risk: key management and 10%+ shareholders are related (Safarik family).
- Limited product revenue (C$426K FY2025) vs operating expenses (C$5.1M) — cash burn rate high.
- Regulatory risk in Australia, Canada, and Israel; any change in controlled substances scheduling could materially impair revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001193125-26-229774 |
| Document: d43258dex11.htm | 0001193125-26-229774 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 26, 2026 21w ago | 6-K | — | awaiting T+20 | — | — |
May 19, 2026 22w ago | F-1/A | $0.2352 | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | F-1/A | $0.2644 $0.2352 | ▼ −11.04% | ▼ −15.07% | — |
Apr 21, 2026 26w ago | F-1/A | $0.2680 $0.2352 | ▼ −12.24% | ▼ −15.40% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers